相似文献
1
PARP inhibition: PARP1 and beyond.
Nat Rev Cancer. 2010 Apr;10(4):293-301. doi: 10.1038/nrc2812. Epub 2010 Mar 4.
2
PARP inhibitors for cancer therapy.
Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. doi: 10.1017/S146239940500904X.
3
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Biochem Pharmacol. 2016 May 1;107:29-40. doi: 10.1016/j.bcp.2016.02.015. Epub 2016 Feb 24.
4
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
PLoS One. 2015 Oct 27;10(10):e0140988. doi: 10.1371/journal.pone.0140988. eCollection 2015.
5
New PARP targets for cancer therapy.
Nat Rev Cancer. 2014 Jul;14(7):502-9. doi: 10.1038/nrc3748. Epub 2014 Jun 5.
6
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
J Natl Cancer Inst. 2004 Jan 7;96(1):56-67. doi: 10.1093/jnci/djh005.
7
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):39-53. doi: 10.2174/157489206775246430.
8
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Clin Cancer Res. 2003 Jul;9(7):2711-8.
9
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Clin Cancer Res. 2005 May 1;11(9):3402-9. doi: 10.1158/1078-0432.CCR-04-2353.
10
Mitotic functions of poly(ADP-ribose) polymerases.
Biochem Pharmacol. 2019 Sep;167:33-43. doi: 10.1016/j.bcp.2019.03.028. Epub 2019 Mar 22.
引用本文的文献
1
Posttranscriptional RNA stabilization of telomeric RNAs FRG2, DBE-T, D4Z4 at human 4q35 in response to genotoxic stress and D4Z4 macrosatellite repeat length.
Clin Epigenetics. 2025 May 4;17(1):73. doi: 10.1186/s13148-025-01881-5.
2
Proteome-wide microarray-based screening of PAR-binding proteins.
Nucleic Acids Res. 2025 Apr 10;53(7). doi: 10.1093/nar/gkaf300.
3
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review).
Oncol Lett. 2025 Mar 4;29(5):215. doi: 10.3892/ol.2025.14961. eCollection 2025 May.
4
Research for a Common Thread: Insights into the Mechanisms of Six Potential Anticancer Agents.
Molecules. 2025 Feb 24;30(5):1031. doi: 10.3390/molecules30051031.
5
Early Detection of the Pathogenetic Variants of Homologous Recombination Repair Genes in Prostate Cancer: Critical Analysis and Experimental Design.
Biology (Basel). 2025 Jan 23;14(2):117. doi: 10.3390/biology14020117.
6
Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition.
J Phys Chem B. 2025 Feb 27;129(8):2175-2186. doi: 10.1021/acs.jpcb.4c07960. Epub 2025 Feb 17.
7
RECQL4 requires PARP1 for recruitment to DNA damage, and PARG dePARylation facilitates its associated role in end joining.
Exp Mol Med. 2025 Feb;57(1):264-280. doi: 10.1038/s12276-024-01383-z. Epub 2025 Jan 28.
8
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer.
Mol Ther Oncol. 2024 Nov 23;32(4):200911. doi: 10.1016/j.omton.2024.200911. eCollection 2024 Dec 19.
9
Colon-Targeted Poly(ADP-ribose) Polymerase Inhibitors Synergize Therapeutic Effects of Mesalazine Against Rat Colitis Induced by 2,4-Dinitrobenzenesulfonic Acid.
Pharmaceutics. 2024 Dec 2;16(12):1546. doi: 10.3390/pharmaceutics16121546.
10
Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.
Future Med Chem. 2025 Jan;17(1):35-58. doi: 10.1080/17568919.2024.2437972. Epub 2024 Dec 18.
本文引用的文献
1
Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Biochemistry. 2010 Feb 16;49(6):1056-8. doi: 10.1021/bi902079y.
2
PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA.
J Biol Chem. 2010 Mar 12;285(11):8054-60. doi: 10.1074/jbc.M109.077834. Epub 2010 Jan 11.
3
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.
4
Structural and biophysical studies of human PARP-1 in complex with damaged DNA.
J Mol Biol. 2010 Feb 5;395(5):983-94. doi: 10.1016/j.jmb.2009.11.062. Epub 2009 Dec 4.
5
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
J Med Chem. 2009 Nov 26;52(22):7170-85. doi: 10.1021/jm901188v.
6
Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells.
J Biol Chem. 2009 Dec 4;284(49):33926-38. doi: 10.1074/jbc.M109.023879. Epub 2009 Oct 7.
7
Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications.
J Am Chem Soc. 2009 Oct 14;131(40):14258-60. doi: 10.1021/ja906135d.
8
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.
Nature. 2009 Oct 1;461(7264):614-20. doi: 10.1038/nature08356. Epub 2009 Sep 16.
9
New functions for an ancient domain.
Nat Struct Mol Biol. 2009 Sep;16(9):904-7. doi: 10.1038/nsmb0909-904.
10
A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation.
Nat Struct Mol Biol. 2009 Sep;16(9):923-9. doi: 10.1038/nsmb.1664. Epub 2009 Aug 13.
Zotero 插件